ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: SA-PO565

Uromodulin in Kidney Failure

Session Information

Category: Dialysis

  • 801 Dialysis: Hemodialysis and Frequent Dialysis

Authors

  • McGill, Rita L., University of Chicago Division of the Biological Sciences, Chicago, Illinois, United States
  • Chapman, Arlene B., University of Chicago Division of the Biological Sciences, Chicago, Illinois, United States
Background

Uromodulin (UMOD) is a 95 kDa glycoprotein produced exclusively by the loop of Henle. UMOD is detectable in urine and blood and levels may represent functional renal tubular mass. To address this question, we measured serum UMOD in chronic dialysis patients to evaluate its potential utility as biomarker of kidney function and to assess its dialyzability.

Methods

Serum samples were obtained immediately before and after hemodialysis through dialysis access and immediately frozen at -20. All samples were assayed undiluted within 6 months, using a sandwich ELISA assay platform (Invitrogen ®; Thermo-Fisher), with assay sensitivity down to 40 pg/mL. Estimated glomerular filtration rate (eGFR) was determined using the median of all available pre-dialysis eGFR values within a month of the sample collection date. Age, sex, dialysis vintage, and target weight were collected. Descriptive analyses and Spearman correlation coefficients were performed.

Results

Pre- and post-dialysis levels were obtained from 38 individuals. Values were non-normally distributed (Fig1). Median UMOD pre-dialysis was 2450 (IQR=1060- 5981) pg/mL, and post dialysis was 2870 (IQR=1050-5640) pg/mL, with median difference =16 (!QR=-600-470) pg/mL, P=0.8. UMOD>8000 pg/mL were in the 95th percentile. Pre- and post- dialysis UMOD values were highly correlated (R=0.93, P<0.001 and did not correlate with eGFR, age, sex, dialysis vintage or target weight.

Conclusion

Low levels of UMOD are detectable in patients with end stage kidney failure. There is no evidence of removal of UMOD with hemodialysis. Further evaluation of UMOD as a biomarker of potential kidney recovery after acute injury or transplantation or indicator of preserved residual renal function is worth further investigation.

Uromodulin Levels Before and After Hemodialysis